Kymera Therapeutics stock slides nearly 7% after CEO share-sale filing — what KYMR investors watch next
NEW YORK, Jan 2, 2026, 15:39 ET — Regular session Kymera Therapeutics Inc (KYMR.O) shares fell nearly 7% on Friday afternoon after a regulatory filing disclosed a year-end sale by Chief Executive Nello Mainolfi. Kymera was down 6.9% at $72.42, after earlier touching $72.18. The move matters because Kymera has become a high-sensitivity biotech name, with investor expectations tied closely to clinical progress for its experimental immunology drug KT-621. In that setup, insider selling can test sentiment, even when the transactions are scheduled in advance. Friday’s drop stood out against a steadier tape. The SPDR S&P Biotech ETF (XBI) was